Subhakar Mutyala

Subhakar Mutyala

Auto-generated profile, based on publicly available information

Subhakar Mutyala

Department of Radiation Oncology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in Brachytherapy
Verified
Journal Article
Closed access
ASAlexandra Stewart
Alexandra Stewart
BPB. Parashar
B. Parashar
MPM. Patel
M. Patel
DOD. O'FArrell
D. O'FArrell
MBM. Biagioli
M. Biagioli
SMS. Mutyala
S. Mutyala

1 November 2007 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
MBMatthew C. Biagioli
Matthew C. Biagioli
MHMark Harvey
Mark Harvey
EREloy Roman
Eloy Roman
LRLuis E. Raez
Luis E. Raez
AWAaron H. Wolfson
Aaron H. Wolfson
AMArnold Markoe
Arnold Markoe

1 January 2012 in Gynecologic Oncology
Verified
Journal Article
Open access
MEMark H. Einstein
Mark H. Einstein
MFMarina Frimer
Marina Frimer
DKDennis Y.-S. Kuo
Dennis Y.-S. Kuo
LRLaura L. Reimers
Laura L. Reimers
KMKeyur Mehta
Keyur Mehta
GGGary L. Goldberg
Gary L. Goldberg
To evaluate the safety and survival in women treated with adjuvant pelvic radiation "sandwiched" between six cycles of paclitaxel and carboplatin chemotherapy with completely resected UPSC. Surgically staged women with UPSC (FIGO stage 1-4) and no visible residual disease were enrolled. Treatment involved paclitaxel (175 mg/m(2)) and carboplatin (AUC=6.0-7.5) every 21 days for 3 doses, followed by radiation therapy (RT), followed by an additional 3 cycles of paclitaxel and carboplatin (AUC=5-6). Survival analysis, using Kaplan-Meier methods, was performed on patients who completed at least 3 cycles of chemotherapy and RT. A total of 81 patients were enrolled, of which 72 patients completed the first 3 cycles of chemotherapy followed by prescribed RT. Median age was 67 years (range: 43-82 years). 59/72 (82%) had disease confined to the uterus and 13/72 (18%) had completely resected extra-uterine disease (stage 3 and 4). 65 (83%) completed the protocol. Overall PFS and OS for combined stage 1 and 2 patients was 65.5 ± 3.6 months and 76.5 ± 4.3 months, respectively. PFS and OS for combined stage 3 and 4 patients was 25.8 ± 3.0 and 35.9 ± 5.3 months, respectively. Three-year % survival probability for stage 1 and 2 patients was 84% and for stage 3 and 4 patients was 50%. Of the 435 chemotherapy cycles administered, there were 11(2.5%) G3/G4 non-hematologic toxicities. 26(6.0%) cycles had dose reductions and 37(8.5%) had dose delays. Compared to prior studies of single modality adjuvant therapy, RT "sandwiched" between paclitaxel and carboplatin chemotherapy is well-tolerated and highly efficacious in women with completely resected UPSC.

1 September 2009 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
RSRajiv Sharma
Rajiv Sharma
MSMarnee Spierer
Marnee Spierer
SMSubhakar Mutyala
Subhakar Mutyala
NTNitika Thawani
Nitika Thawani
HCHillel W. Cohen
Hillel W. Cohen
SKShalom Kalnicki
Shalom Kalnicki

1 January 2017 in Brachytherapy
Verified
Journal Article
Closed access
ALAnna O. Likhacheva
Anna O. Likhacheva
PDPhillip M. Devlin
Phillip M. Devlin
SSShervin M. Shirvani
Shervin M. Shirvani
CBChristopher A. Barker
Christopher A. Barker
PBPhillip Beron
Phillip Beron
MKMitchell Kamrava
Mitchell Kamrava

1 January 2012 in Gynecologic Oncology
Verified
Journal Article
Open access
MEMark H. Einstein
Mark H. Einstein
MKMerieme Klobocista
Merieme Klobocista
JHJune Y. Hou
June Y. Hou
SLStephen Lee
Stephen Lee
SMSubhakar Mutyala
Subhakar Mutyala
GGGary L. Goldberg
Gary L. Goldberg
Uterine carcinosarcoma (CS) is a rare uterine tumor with an extremely poor prognosis. In the adjuvant setting, efficacy has been shown with radiotherapy (RT), systemic chemotherapy, or both. This is the first report describing the efficacy and toxicity of adjuvant ifosfamide or ifosfamide plus cisplatin "sandwiched" with RT in patients with surgically staged and completely resected uterine carcinosarcoma. Women with surgically staged CS with no gross residual disease were initially administered ifosfamide (1.2 g/m(2)/day×5 days) with cisplatin (20 mg/m(2)/day×5 days) every 3 weeks for 3 cycles followed by pelvic external beam RT and brachytherapy followed by 3 additional cycles of ifosfamide (1.0 g/m2/day) with cisplatin (20 mg/m(2)/day×5 days) every 3 weeks. Similar to the GOG trial in recurrent CS (Sutton et al., 2000), the addition of cisplatin added toxicity without additional efficacy, so mid-study, the cisplatin was eliminated from the regimen. Toxicities were recorded and disease-free survival (DFS) was calculated with Kaplan-Meier statistical methods. In total, 12 patients received ifosfamide and cisplatin and 15 patients received ifosfamide alone, both 'sandwiched' with RT. The median follow up was 35.9 months (range 6-88). The 2 year DFS was similar in both the ifosfamide/cisplatin and ifosfamide groups (log-rank p=0.16), so they were combined for analysis. 19 patients (70%) completed the protocol. As expected, stage 1 patients had a better 2-year DFS (18.75 ± 1.12 months; log-rank p=0.008 when compared to stages 2, 3, 4). Also, in stages 2, 3 and 4 patients, the DFS was 15.81 ± 1.73 months. Grade 3/4 neutropenia, anemia and thrombocytopenia occurred in 18%, 4% and 4% of cycles, respectively. Ifosfamide "sandwiched" with RT appears to be an efficacious regimen for surgically staged CS patients with no residual disease, even in patients with advanced stage. The addition of cisplatin to the regimen added toxicity without improving efficacy. Even with ifosfamide alone, the efficacy of this 'sandwich' regimen comes with a moderate but tolerable toxicity profile.